Anthrax future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 6: | Line 6: | ||
==Newer Agents== | ==Newer Agents== | ||
In May 2009, [[Human Genome Sciences]] submitted a [[Biologic License Application]] (BLA, permission to market) for its new drug, [[raxibacumab]] (brand name ABthrax) intended for emergency treatment of inhaled anthrax.<ref>{{cite news |title=HGSI asks for FDA approval of anthrax drug ABthrax |agency=[[Associated Press]] |newspaper=Forbes |date=21 May 2009 |url=http://www.forbes.com/feeds/ap/2009/05/21/ap6450866.html |deadurl=yes}} | In May 2009, [[Human Genome Sciences]] submitted a [[Biologic License Application]] (BLA, permission to market) for its new drug, [[raxibacumab]] (brand name ABthrax) intended for emergency treatment of inhaled anthrax.<ref>{{cite news |title=HGSI asks for FDA approval of anthrax drug ABthrax |agency=[[Associated Press]] |newspaper=Forbes |date=21 May 2009 |url=http://www.forbes.com/feeds/ap/2009/05/21/ap6450866.html |deadurl=yes}} | ||
==References== | ==References== |
Revision as of 20:10, 16 July 2014
Anthrax Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Anthrax future or investigational therapies On the Web |
American Roentgen Ray Society Images of Anthrax future or investigational therapies |
Risk calculators and risk factors for Anthrax future or investigational therapies |
Overview
Given the safety and efficacy of current vaccines and antibiotics, there are not a large number of new agents under development to treat anthrax.
Newer Agents
In May 2009, Human Genome Sciences submitted a Biologic License Application (BLA, permission to market) for its new drug, raxibacumab (brand name ABthrax) intended for emergency treatment of inhaled anthrax.<ref>"HGSI asks for FDA approval of anthrax drug ABthrax". Forbes. Associated Press. 21 May 2009.